immunogenic

(redirected from immunogenicity)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to immunogenicity: humoral immunity

immunogenic

[¦im·yə·nō¦jen·ik]
(immunology)
Producing immunity.
References in periodicals archive ?
Because biotherapeutic development becomes increasingly costly as it moves downstream, it is important to anticipate immunogenicity as far upstream as possible in the drug discovery process.
Immunogenicity through the induction of anti-drug-antibodies (ADA) is now known to be one of the main causes for this loss of response and may also be responsible for safety issues (5).
Immunogenicity is defined by the US Food and Drug Administration as the propensity of the therapeutic protein product to generate immune responses to itself and to related proteins or to induce immunologically-related adverse clinical events.
This Phase III, open-label study was conducted to assess the immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine (IIV4) in adults in Brazil.
One next-generation TNF-[alpha] blocker currently in clinical trials, ozoralizumab, has been designed using nanobody technology based on proprietary camelid type single-domain antibody fragments (15) and is expected to show low immunogenicity by design; however, clinical studies will be needed to confirm this.
The manufacturing process may introduce protein modifications that promote immunogenicity.
Arno Jens Kromminga, a pioneer in immunological assays, IPM was involved in the first cases of immunogenicity and brought the first biosimilar erythropoietin to approval in Europe.
8226; Daniel Sikkema, Executive Director, Head of Immunogenicity and Clinical Immunology, GlaxoSmithKline
As a consequence, the current guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins (the "Guideline") (3) states that immunogenicity assessment should be part of the clinical trial process.
Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
Antitope undertakes immunogenicity testing of antibodies and other proteins, engineering of antibodies and proteins to reduce their immunogenicity, and development of manufacturing cell lines.
We are delighted to be working with such an innovative organisation as ChemomAb to generate novel therapeutic antibodies suitable for repeat dose treatments of chronic inflammatory diseases, said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, "This agreement combines ChemomAb's proprietary therapeutic targets and candidate non-human antibodies with Antitope's antibody humanisation and immunogenicity technologies to create powerful new treatments for inflammatory diseases.